Tirzepatide's dual GIP/GLP-1 mechanism makes it distinct from pure GLP-1 agonists like semaglutide or liraglutide
2017-2021 (US$ Billion) Figure 44: Asia Pacific Glucagon-like Peptide-1 (GLP-1) Market by Value
Symptoms developed after 2 weeks to 2 months after the first administration
Key differential aspects of the group of glucagon-like peptide-1 receptor agonist drugs There are several arGLP-1 s approved or under study for the use in DM2: exenatide (exenatide and exenatide LAR or weekly), liraglutide, lixisenatide, dulaglutide, semaglutide, albiglutide (withdrawn from the market), and efpeglenatide (in clinical development)
Instead of working on just one system in your body, it works on two, which may lead to stronger appetite control for some people
Gao, D., Dong, Y., Jia, Z., Bian, C., Zhu, J., Wu, Y., Fang, S., & Gu, S